HBV Treatment
Antiviral Therapy for Chronic Hepatitis B Patients with Decompensated Liver Cirrhosis
- Details
- Category: HBV Treatment
- Published on Tuesday, 16 November 2010 12:48
- Written by Liz Highleyman
Chronic hepatitis B patients with decompensated liver cirrhosis can be treated safely and effectively with antiviral agents, according to a systematic review presented at the recent American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) in Boston. Entecavir (Baraclude) has demonstrated good potency, matching that of lamivudine, but without resistance; newer agents such as tenofovir (Viread) require further study in this population.
Bristol-Myers Squibb Enhances Co-pay Assistance Program for Entecavir (Baraclude) for Hepatitis B
- Details
- Category: HBV Treatment
- Published on Tuesday, 16 November 2010 12:48
- Written by Bristol-Myers Squibb
Bristol-Myers Squibb this summer expanded its co-pay benefit program for individuals receiving or wishing to use entecavir (Baraclude) who have private insurance policies with out-of-pocket costs. The enhanced program will save eligible patients up to $200 per month for 4 years. Eligible participants may request a Co-Pay Benefit Card from their healthcare providers.
Add-on Adefovir Is More Effective and Durable Than Switch to Entecavir as Rescue Therapy
- Details
- Category: HBV Treatment
- Published on Tuesday, 09 November 2010 12:48
- Written by Liz Highleyman
Adding adefovir (Hepsera) is more effective and durable than switching to entecavir (Baraclude) as rescue therapy for Epivir-resistant patients with chronic hepatitis B, according to a study presented in Boston last week at AASLD 2010. The mean reduction of serum HBV DNA levels was significantly less in the entecavir group than in the add-on adefovir group at weeks 24 and 48. In addition, the rate of undetectable HBV DNA was significantly lower in the entecavir group than in the add-on adefovir group.
Are IL28B Gene Variations Associated with Outcomes in People with Hepatitis B?
- Details
- Category: HBV Treatment
- Published on Friday, 12 November 2010 12:48
- Written by Liz Highleyman
IL28B gene patterns may influence response to interferon therapy for hepatitis B, but this is not as straightforward as it is for hepatitis C, according to a set of studies presented at the recent American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) in Boston. Two analyses suggested that people with the protective rs12979860 C/C pattern were more likely to achieve sustained virological suppression with interferon, but less likely to experience HBeAg seroconversion. A third study, however, found no link between rs12979860 pattern and hepatitis B or HIV persistence or progression.
Telbivudine and Elective Cesarean Section Help Prevent Mother-to-child Hepatitis B Transmission
- Details
- Category: HBV Treatment
- Published on Tuesday, 09 November 2010 12:48
- Written by Liz Highleyman
Treatment with the nucleoside analog telbivudine (Tyzeka) and birth by elective Cesarean section both reduced the likelihood of hepatitis B virus (HBV) transmission from mothers to infants during pregnancy and delivery, according to 2 separate studies presented at the recent American Association for the Study of Liver Diseases "Liver Meeting" (AASLD 2010) this week in Boston. Emergency Cesarean delivery, however, was associated with a trend toward increased transmission risk.
More Articles...
- Which Pegylated Interferon alfa-2b Regimen Works Best for Chronic Hepatitis B?
- Tenofovir (Viread) Maintains HBV Suppression without Resistance for 4 Years
- FDA Approves Entecavir (Baraclude) for Chronic Hepatitis B Patients with Decompensated Liver Disease
- Add-on adefovir (Hepsera) Is More Effective and Durable Than a Switch to entecavir (Baraclude) as Rescue Therapy for Epivir-resistant Patients with Chronic Hepatitis B
Web Design and Development by